Table 2 RFS stratified step-wise multivariate Cox model with TLE3 cut-point of 30%

From: TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial

Visual IHC factor

Hazard ratio

95% CI

P -value a

Treatment (Trt) EC/T vs CEF

0.84

0.33–2.12

0.715

TLE3+ vs TLE3−

0.95

0.49–1.82

0.869

Endocrine therapy

0.17

0.08–0.38

<0.0001

Anti-HER2 therapy

3.63

1.82–7.25

0.0003

Interaction of TLE3 and Trt

0.81

0.29–2.24

0.682

Interaction of endocrine therapy and Trt

1.91

0.86–4.24

0.114

Interaction of anti-HER2 therapy and Trt

0.57

0.16–2.07

0.393

Ariol Image analysis

Factor

 Trt EC/T vs CEF

0.60

0.26–1.36

0.219

 TLE3+ vs TLE3−

0.79

0.45–1.39

0.416

 Endocrine therapy

0.23

0.11–0.49

0.0001

 Anti-HER2 therapy

3.40

1.77–6.56

0.0003

 Interaction of TLE3 and Trt

1.42

0.58–3.43

0.443

 Interaction of endocrine therapy and Trt

1.38

0.65–2.90

0.402

 Interaction of anti-HER2 therapy and Trt

0.56

0.16–1.98

0.360

  1. Abbreviations: 95% CI=95% confidence interval; IHC=immunohistochemistry; RFS= relapse-free survival; Trt=Treatment; Visual IHC=TLE3 staining assessed visually. Ariol image analysis=TLE3 staining assessed using automated image analysis.
  2. aP-value is based on Wald statistic.
Back to article page